What are the recommended pulmonary vasodilator treatment options, dosing, and monitoring for a patient with congenital heart disease who has developed pulmonary arterial hypertension?

Pulmonary Vasodilators in Congenital Heart Disease

Primary Recommendation

For symptomatic adults with Eisenmenger syndrome and ASD or VSD, bosentan is the first-line pulmonary vasodilator therapy, with PDE-5 inhibitors (sildenafil or tadalafil) as reasonable alternatives or combination therapy if monotherapy fails. 1

---

Diagnostic Confirmation and Risk Assessment

Before initiating pulmonary vasodilator therapy, confirm the diagnosis and severity through:

• Cardiac catheterization is mandatory to accurately measure pulmonary vascular resistance (PVR ≥2.5 Wood units indicates need for PAH expert consultation), mean pulmonary arterial pressure, and pulmonary capillary wedge pressure 1, 2
• Transthoracic echocardiography alone is insufficient for accurate PA pressure determination and must be combined with catheterization data when making treatment decisions 1
• BNP levels, chest x-ray, and 6-minute walk test provide baseline assessment for monitoring treatment response 1
• Exclude other contributors to pulmonary hypertension including left heart disease, lung parenchymal disease, chronic thromboembolic disease, and anatomic obstructions 1

---

Treatment Selection by Clinical Scenario

Eisenmenger Syndrome (Class I Evidence)

Bosentan monotherapy:

• Starting dose: typically initiated at lower doses and titrated based on tolerance 1
• Proven beneficial in symptomatic adults with Eisenmenger syndrome with ASD or VSD (Class I, Level A recommendation) 1
• Improves 6-minute walk distance by approximately 49 meters and NYHA functional class by 0.33 points 3
• Well-tolerated with serious adverse event rates of 4.8-8.7% 3

PDE-5 inhibitors (sildenafil or tadalafil):

• Reasonable alternative to bosentan for symptomatic Eisenmenger patients (Class IIa, Level B-NR) 1
• Sildenafil improves 6-minute walk distance by approximately 60 meters and NYHA class by 0.58 points 3
• Dosing for sildenafil: 20 mg three times daily (standard PAH dosing) 4
• Chronic use not recommended in children due to increased mortality with higher doses 4

Combination therapy:

• Bosentan plus PDE-5 inhibitor is reasonable if symptomatic improvement does not occur with either medication alone (Class IIa, Level B-R) 1
• Combination therapy improves NYHA class by 0.62 points compared to placebo 3

Eisenmenger Syndrome with Complex Lesions

Bosentan remains reasonable therapy for:

• Shunts other than ASD/VSD (e.g., PDA, aortopulmonary window) - Class IIa, Level C-EO 1
• Complex congenital heart lesions - Class IIa, Level C-EO 1
• Patients with Down syndrome - Class IIa, Level B-NR 1

PAH with Prevalent Systemic-to-Pulmonary Shunts

Before initiating vasodilators:

• Cardiac catheterization with hemodynamics is required to assess suitability for defect closure 1
• Consider mechanical interventions (defect closure) as part of short-term management, but recognize that even modest residual PAH determines long-term outcomes 1
• Vasoreactivity testing should be performed using short-acting agents (IV epoprostenol, adenosine, or inhaled nitric oxide) 1

If vasoreactive (fall in mean PA pressure ≥10 mmHg to ≤40 mmHg with stable/increased cardiac output):

• Trial of high-dose calcium channel blockers is reasonable 1

If non-vasoreactive:

• Apply same treatment algorithm as Eisenmenger syndrome (bosentan or PDE-5 inhibitors) 1

PAH After Defect Correction

This represents the highest-risk subgroup with worst prognosis requiring aggressive treatment 5:

• Initiate disease-targeting therapy proactively with bosentan or PDE-5 inhibitors 5
• Consider continuous IV epoprostenol for high-risk patients (NYHA Class IV, rapidly progressive symptoms) 6
• Epoprostenol dosing: Start at 2 ng/kg/min, increase by 2 ng/kg/min increments every 15 minutes until tolerance limit or dose-limiting effects occur 6
• Mean effective doses in trials: 11.2 ng/kg/min at 12 weeks, with incremental increases of 2-3 ng/kg/min every 3 weeks 6

PAH with Small/Coincidental Defects

• Treat similarly to idiopathic PAH as defects do not account for elevated PVR 1
• Defect closure is contraindicated 1
• Apply standard PAH treatment algorithms with bosentan or PDE-5 inhibitors 1

---

Monitoring and Follow-Up

Regular assessments every 3-6 months should include:

• NYHA functional class 1, 7
• 6-minute walk distance (target >440 meters, though lower acceptable in elderly or with comorbidities) 7
• BNP/NT-proBNP levels 1, 7
• Transthoracic echocardiography 1
• Periodic cardiac catheterization when clinical status changes or treatment escalation considered 1

Treatment goals:

• Achieve and maintain NYHA functional class I-II 7
• Improve or stabilize 6-minute walk distance 7
• Reduce right ventricular dysfunction on imaging 7

---

Supportive Care Measures

All patients with PAH-CHD should receive:

• Supplemental oxygen to maintain saturations ≥90% at all times 1, 2
• Diuretics for fluid retention with careful monitoring of electrolytes and renal function 2, 7
• Anticoagulation should be considered in PAH-CHD, though evidence is less robust than in idiopathic PAH 1
• Pregnancy avoidance or termination is strongly recommended 1
• Non-estrogen contraception (intrauterine device preferred) 1

---

Critical Pitfalls to Avoid

• Never use calcium channel blockers empirically without documented acute vasoreactivity testing 1
• Never combine riociguat with PDE-5 inhibitors - absolute contraindication 7
• Do not rely on echocardiography alone for treatment decisions - catheterization is mandatory 1
• Avoid abrupt withdrawal of epoprostenol or sudden large dose reductions except in life-threatening situations 6
• Do not use conventional vasodilators (ACE inhibitors, ARBs, beta-blockers) unless required for specific comorbidities 2, 7

---

Collaborative Management

All patients with ACHD and PVR ≥2.5 Wood units should be assessed collaboratively by:

• An ACHD cardiologist 1
• A pulmonary hypertension expert 1
• Management at specialized centers with expertise in both ACHD and PAH 1, 7

This dual expertise is necessary because ACHD and pulmonary vascular disease have "increasingly disparate but complementary bodies of knowledge" required for optimal outcomes 1.

---

Advanced Therapies

Consider lung transplantation for:

• Inadequate response to maximal medical therapy 2, 7
• Persistent NYHA Class III-IV despite combination therapy 2
• Referral should occur soon after inadequate response is confirmed on maximal combination therapy 7

Balloon atrial septostomy:

• May be considered as palliative or bridging procedure in patients deteriorating despite maximal medical therapy 2, 7